Introduction. Sarcoidosis is a chronic granulomatous disease, which can involve different organs and systems. Coexistence of sarcoidosis and spondyloarthritis has been reported in numerous case reports. Purpose. To determine the prevalence of sacroiliitis and spondyloarthritis in patients previously diagnosed with sarcoidosis and to investigate any possible relation with clinical findings. Materials and Methods. Forty-two patients with sarcoidosis were enrolled in the study. Any signs and symptoms in regard to spondyloarthritis (i.e., existence of inflammatory back pain, gluteal pain, uveitis, enthesitis, dactylitis, inflammatory bowel disease, and psoriasis) were questioned in detail and biochemical tests were evaluated. Sacroiliac joint imaging and lateral heel imaging were performed in all patients. Results. Sacroiliitis was found in 6 of the 42 (14.3%) sarcoidosis patients and all of these patients were female. Common features of the disease in these six patients were inflammatory back pain as the major clinical complaint, stage 2 sacroiliitis as revealed by radiological staging, and the negativity of HLA B-27 test. These six patients with sacroiliitis were diagnosed with spondyloarthritis according to the criteria of ASAS and of ESSG. Conclusion. We found spondyloarthritis in patients with sarcoidosis at a higher percentage rate than in the general population (1–1.9%). Controlled trials involving large series of patients are required for the confirmation of the data. 1. Introduction Sarcoidosis is a systemic disease characterized by the involvement of multiple tissues and organs with a noncalcified granuloma reaction, which is not yet well understood [1]. Although the exact pathogenesis of sarcoidosis is not known, it is currently accepted that, in genetically susceptible individuals, it is caused through alteration of the cellular immune response after exposure to an environmental, occupational, or infectious agent [2]. Accumulations of Th1 and macrophages with increased production of proinflammatory cytokines induce the inflammatory cascade and consecutive impairment in tissue permeability; increase in cellular influx and local cellular proliferation cause the formation of granulomas [3]. The crucial pathological finding of sarcoidosis is noncalcified epitheloid cellular granulomas [4]. Sarcoidosis is a chronic granulomatous disease that may present with various clinical findings. It may mimic a number of primary rheumatic diseases and/or accompany them [5]. The disease most frequently presents with bilateral hilar lymphadenopathy and
References
[1]
L. S. Newman, C. S. Rose, and L. A. Maier, “Sarcoidosis,” The New England Journal of Medicine, vol. 336, pp. 1224–1234, 1997.
[2]
S. Hofmann, A. Franke, A. Fischer et al., “Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis,” Nature Genetics, vol. 40, no. 4, pp. 1103–1106, 2009.
[3]
E. S. Chen and D. R. Moller, “Etiology of sarcoidosis,” Clinics in Chest Medicine, vol. 29, no. 3, pp. 365–377, 2008.
[4]
A. Smith, I. Brownell, M. Sanchez, and S. Prystowsky, “Advances in the genetics of sarcoidosis,” Clinical Genetics, vol. 73, no. 5, pp. 401–412, 2008.
[5]
T. Pettersson, “Rheumatic features of sarcoidosis,” Current Opinion in Rheumatology, vol. 10, no. 1, pp. 73–78, 1998.
[6]
J. M. Gumpel, C. J. Johns, and L. E. Shulman, “The joint disease of sarcoidosis,” Annals of the Rheumatic Diseases, vol. 26, no. 3, pp. 194–205, 1967.
[7]
I. Spilberg, L. E. Siltzbach, and C. McEwen, “The arthritis of sarcoidosis,” Arthritis & Rheumatism, vol. 12, no. 2, pp. 126–137, 1969.
[8]
J. A. Smith, E. M？rker-Hermann, and R. A. Colbert, “Pathogenesis of ankylosing spondylitis: current concepts,” Best Practice and Research: Clinical Rheumatology, vol. 20, no. 3, pp. 571–591, 2006.
[9]
I. Kotter, H. Durk, and J. G. Saal, “Sarcoiliitis in sarcoidosis: case reports and review of the literature,” Clinical Rheumatology, vol. 14, no. 6, pp. 695–700, 1995.
[10]
K. Bhamra and R. Stevens, “Pulmonary sarcoidosis following etanercept treatment,” Case Reports in Rheumatology, vol. 2012, Article ID 724013, 4 pages, 2012.
[11]
A. Calin, J. Porta, J. F. Fries, and D. J. Schurman, “Clinical history as a screening test for ankylosing spondylitis,” Journal of the American Medical Association, vol. 237, no. 24, pp. 2613–2614, 1977.
[12]
M. Dougados, S. van der Linden, R. Juhlin et al., “The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy,” Arthritis & Rheumatism, vol. 34, no. 10, pp. 1218–1227, 1991.
[13]
M. Rudwaleit, D. van der Heijde, R. Landewé et al., “The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 777–783, 2009.
[14]
S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis & Rheumatism, vol. 27, no. 4, pp. 361–368, 1984.
[15]
W. Chatham, “Rheumatic manifestations of systemic disease: sarcoidosis,” Current Opinion in Rheumatology, vol. 22, no. 1, pp. 85–90, 2010.
[16]
H. Visser, K. Vos, E. Zanelli et al., “Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors,” Annals of the Rheumatic Diseases, vol. 61, no. 6, pp. 499–504, 2002.
[17]
N. Erb, M. J. Cushley, D. G. Kassimos, R. M. Shave, and G. D. Kitas, “An assessment of back pain and the prevalence of sacroiliitis in sarcoidosis,” Chest, vol. 127, no. 1, pp. 192–196, 2005.
[18]
C. Pacheco-Tena, D. L. B. Alvarado, Y. Lopez-Vidal, et al., “Bacterial DNA in synovial fluid cells of patients with juvenile onset spondyloarthropathies,” Rheumatology, vol. 40, no. 8, pp. 920–927, 2001.
[19]
M. Grosser, D. D. Dittert, T. Luther et al., “Molecular detection of M. tuberculosis DNA in tuberculosis and sarcoidosis,” Diagnostic Molecular Pathology, vol. 10, no. 1, pp. 66–67, 2001.
[20]
D. Nowack and K. M. Goebel, “Genetic aspects of sarcoidosis,” Archives of Internal Medicine, vol. 147, no. 3, pp. 477–481, 1987.
[21]
M. J. Smith, C. W. G. Turton, M. Turner-Warwick, L. M. Morris, and S. D. Lawler, “Association of HLA B8 with spontaneous resolution in sarcoidosis,” Thorax, vol. 36, no. 4, pp. 296–298, 1981.
[22]
D. M. Altmann and R. J. Boyton, “Models of sarcoidosis,” Drug Discovery Today: Disease Models, vol. 3, no. 1, pp. 21–25, 2006.
[23]
J. Braun, M. Bollow, G. Remlinger, et al., “Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors,” Arthritis & Rheumatology, vol. 41, pp. 58–67, 1998.
[24]
A. Abouzahir, A. El Maghraoui, F. Tabache et al., “Sarcoidose et spondyloarthrite ankylosante,” Annales de Medecine Interne, vol. 153, no. 6, pp. 407–410, 2002.
